Humanigen Announces Closing of Public Offering of Common Stock
September 22 2020 - 2:00PM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN), a clinical stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm’ with its lead drug
candidate lenzilumab™, announced today that it has completed its
previously announced underwritten public offering of common stock.
Humanigen raised net proceeds of approximately $72.8 million from
the sale of 9,200,000 shares in the offering, including 1,200,000
shares sold upon the full exercise by the underwriters of their
over-allotment option, after deducting the underwriting discounts
and commissions and estimated offering costs.
J.P. Morgan and Jefferies acted as joint book-running managers
for the offering. Bryan, Garnier & Co. acted as the European
lead manager and National Securities Corporation, Roth Capital
Partners and H.C. Wainwright & Co. acted as co-managers for the
offering.
Humanigen intends to use the net proceeds from the offering to
support its manufacturing, production and commercial preparation
activities relating to lenzilumab as a potential therapy for
COVID-19 patients and for general corporate purposes.
The shares were offered by Humanigen pursuant to a shelf
registration statement (including a prospectus) on Form S-3 that
was previously filed with and declared effective by the U.S.
Securities and Exchange Commission (“SEC”). The offering was made
only by means of the written prospectus and prospectus supplement
that form a part of the registration statement. A preliminary
prospectus supplement and a final prospectus supplement relating to
and describing the terms of the offering were filed with the SEC on
September 15, 2020 and September 18, 2020, respectively, and are
available on the SEC’s website at www.sec.gov.
Copies of the final prospectus supplement and accompanying
prospectus relating to the offering may also be obtained from: J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717 Telephone: 866-803-9204
Email: prospectus-eq_fi@jpmorganchase.com; or Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by e-mail at
prospectus_department@jefferies.com or by telephone at (877)
821-7388.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of any securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Forward-Looking Statements
This release contains forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct and you should be
aware that actual events or results may differ materially from
those contained in the forward-looking statements. Words such as
“will,” “expect,” “intend,” “plan,” “potential,” “possible,”
“goals,” “accelerate,” “continue,” and similar expressions identify
forward-looking statements, including, without limitation,
statements regarding the contemplated use of proceeds.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the various risks and
uncertainties described in the “Risk Factors” sections and
elsewhere in the Company's periodic and other filings with the
Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not place undue
reliance on any forward-looking statements, which speak only as of
the date of this release. We undertake no obligation to revise or
update any forward-looking statements made in this press release to
reflect events or circumstances after the date hereof or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200922005914/en/
Media Sean Leous Westwicke, an ICR company
sean.leous@westwicke.com 646-866-4012
Investors Victoria Meissner, MD Westwicke, an ICR company
victoria.meissner@westwicke.com 646-677-1837
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024